Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide as it reconsiders whether the drug is in shortage.
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide as it reconsiders whether the drug is in shortage.
Read More
About Author
